...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMJ: British medical journal >SHORT CUTS
【24h】

SHORT CUTS

机译：捷径

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lorcaserin, a selective serotonin receptor agonist, showed promise as a new weight loss drug in its first large trial. Overweight and obese adults taking the drug lost around 4 kg more in the first year than controls taking placebo (mean weight loss 5.8 kg v 2.2 kg, P5% of their body weight in the first year were randomised again for the trial's second year. Those switching to placebo put weight back on. Those continuing with lorcaserin rebounded less and ended up around 2 kg lighter than controls, on average.The modest weight loss was accompanied by equally modest but potentially more important improvements in markers of cardiovascular risk including blood pressure, serum lipids, and measures of glucose metabolism. These fringe benefits set the new drug apart from orlistat and sibutramine, says an editorial (pp 288-90). A better safety profile also sets lorcaserin apart from its notorious cousins fenfluramine and dexflu-ramine. Both were taken off the market when evidence of damage to heart valves emerged.
机译：选择性5 -羟色胺受体Lorcaserin受体激动剂,显示承诺作为一种新的减肥药物在第一次大审判。成人服用此药损失了大约4公斤多第一年比服用安慰剂控制的意思体重5.8公斤v 2.2公斤,P 5%的体重在第一年随机试验的第二年。这些开关安慰剂把重量。那些继续lorcaserin反弹更少,最终在2公斤比控制,轻平均。由同样温和但可能更重要改善心血管风险的标志包括血压、血清脂质和葡萄糖代谢的措施。设置新的药物除了奥利司他和好处西布曲明,(页288 - 90)的一篇社论说。更好的安全性还设置lorcaserin分开从其臭名昭著的堂兄弟氟苯丙胺和dexflu-ramine。当心脏瓣膜出现损害的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号